Review of zolmitriptan and its clinical applications in migraine

Bibliography

• LIPTON RB, SILBERSTEIN SD, STEWART WF: An update on the epidemiology of migraine. Headache (1994) 34:319–328.
   PubMed Web of Science ®Google Scholar
• JOHANNES CB, LINET MS, STEWART WF, CELENTANTO DD, LIPTON RB, SZKIO M: Relationship of headache to the phase of the menstrual cycle among young women: a daily diary study. Neurology (1995) 45:1076–1082.
   PubMed Web of Science ®Google Scholar
• LIPTON RB, STEWART WF: Migraine in the United States: a review of epidemiology and health care use. Neurology (1993) 43 (Suppl. 3):56–510.
   Google Scholar
• CLARKE CE, MACMILLAN L, SONDHI S, WELLS NE: Economic and social impact of migraine. Q. J. Med. (1996) 89:77–84.
   Google Scholar
• OSTERHAUS JT, TOWNSEND RJ, GANDEK B, WARE JE JR: Measuring the functional status and well being of patients with migraine headache. Headache (1994) 34:337–343.
   PubMed Web of Science ®Google Scholar
• LIPTON RB, STEWART WE VON KORFF M: The burden of migraine. A review of cost to society. PharmacoEconomics (1994) 6:215–221.
   PubMed Web of Science ®Google Scholar
• DAHLOF C, DIMENAS E: Migraine patients experience poorer subjective well being/quality of life even between attacks. Cephalalgia (1995) 15:31–36.
   PubMed Web of Science ®Google Scholar
• STEWART WE SHE CHTER A, LIPTON RB: Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology (1994) 44\(Suppl. 4):24–39.
   Google Scholar
• LIPTON RB, STEWART WE SIMON D: Medical consultation for migraine: results from the American Migraine Study. Headache (1998a) 38:87–96.
   PubMed Web of Science ®Google Scholar
• MOUNSTEPHEN AH, HARRISON RK: A study of migraine and its effects in a working population. Occup. Med. (London) (1995) 45:311–317.
   PubMedGoogle Scholar
• SAKAI E IGARASHI H: Epidemiology ofmigraine in Japan. Cephalagia (1997) 17:15–22.
   Google Scholar
• LIPTON RB, STEWART WE LIBERMAN J, KOLODNER K, STEINER TJ: Patterns of healthcare utilisation for migraine in England. Cephalalgia (1999b) 19:305.
   Web of Science ®Google Scholar
• STANG PE, VON KORFF M: The diagnosis of headache in primary care: factors in the agreement of clinical and standardised diagnosis. Headache (1994) 34:138–142.
   PubMed Web of Science ®Google Scholar
• EDMEADS J, FINDLAY H, TUGWELLP, PRYSE-PHILLIPS W, NELSON RE MURRAY TJ: Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can..). Neurol Sri. (1993) 20:131–137.
   PubMed Web of Science ®Google Scholar
• FORWARD SP, MCGRATH PJ, MACKINNON D, BROWN TL, SWANN J, CURRIE EL: Medication patterns of recurrent headache sufferers: a community study. Cephalalgia (1998) 18:146–151.
   PubMed Web of Science ®Google Scholar
• HOLMES WE MACGREGOR EA, SAWYER JP, LIPTON RB: Information about migraine disability influences physicians perceptions of illness severity and treatment. Headache (2001) 41(4):343–350.
   PubMedGoogle Scholar
• LIPTON RB, STEWART WF, STONE AM, LAINEZ JA, SAWYER JPC: Stratified care versus step care strategies for migraine. JAMA (2000) 284:2599–2605.
   PubMed Web of Science ®Google Scholar
• KOSINSKI M, GARBER WH, DIAMOND M et al.: HIT-6 scores discriminate among headache sufferers differing in headache associated workplace productivity loss. World Congress of Neurology London, UK (June 2001).
   Google Scholar
• ISLER H: Historical background. In: The Headaches. Olsen J, Tfelt-Hansen P, Welch KMA (eds), Raven Press, New York, USA (1993):1–8.
   Google Scholar
• LEAO AAP: Spreading depression of activity in cerebral cortex. Neurophysiol (1944) 7:359–390.
   Google Scholar
• LAURITZEN M: Cerebral blood flow in migraine and spreading depression. Acta. Neurol Scand. (1987) 76\(Suppl. 113):1–40.
   Google Scholar
• LANCE JW: Current concepts of migraine pathogenesis. Neurology (1993) 43 (Suppl. 3):S11–515.
   Google Scholar
• SILBERSTEIN SD: The pharmacology of ergotamine and dihydroergotamine. Headache (1997) 37\(Suppl. 1):515–525.
   Google Scholar
• PERRIN VL: Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin. Pharmacokinet. (1985) 10:334–352.
   PubMed Web of Science ®Google Scholar
• PEROUTKA SJ: 5-Hydroxytryptamine receptor subtypes and the pharmacology of migraine. Neurology (1993) 43 (Suppl. 3):S34–S38.
   Google Scholar
• HUSSEY EK, DONN KH, BUSCH MA, FOX AW, POWELL JR: Pharmacokinetics (PK) or oral sumatriptan in migraine patients during an attack and while painfree. Pharmacol Ther. (1991) 49:134.
   Google Scholar
• FOWLER PA, LACEY LF, THOMAS M et al.: The clinical pharmacology, pharma-cokinetics and metabolism of sumatriptan. Eur: Neurol (1991) 31:291–294.
   PubMed Web of Science ®Google Scholar
• BATES D, ASHFORD E, DAWSON R et al.: Subcutaneous sumatriptan during the migraine aura. Neurology (1994) 44:1587–1592.
   PubMed Web of Science ®Google Scholar
• DAHLOF C: Would any acute treatment formigraine demonstrate recurrence? Cephalalgia (1997) 17\(Suppl. 17):17–20.
   Google Scholar
• MACINTYRE P, GEMMILL J, HOGG K, BHARGAVA B: The effect of subcutaneous sumatriptan (GR43175) on central haemodynamics and the coronary circulation. Clin. Pharmacol Ther. (1992) 51:152.
   Web of Science ®Google Scholar
• VISSER WH, DE VRIEND RHM, JASPERS NWMH, FERRARI MD: Sumatriptan in the clinical practice: a 2-year review of 453 migraine patients. Neurology (1996) 47:46–51.
   PubMed Web of Science ®Google Scholar
• RAPOPORT AM, RAMADAN NM, ADELMAN JU et al.: Optimising the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine: a multi-centre, double-blind, placebo-controlled dose-range-finding study. Neurology (1997) 49:1210–1218.
   PubMed Web of Science ®Google Scholar
• SOLOMON GD, CADY RK, KLAPPER JA, EARL NL, SAPER JR, RAMADAN NM: Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology (1997) 49:1219–1225.
   Google Scholar
• GALLAGHER RIVI, DENNISH G, SPIERINGS ELH, CHITRA R: A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache (2000) 40:119–128.
   PubMedGoogle Scholar
• RYAN RE JR, DIAMOND S, GIAMMARCO RAM, AURORA SK, REED RC, FLETCHER PE: Efficacy of zolmitriptan at early time-points for the acute treatment of migraine and treatment of recurrence. CNS Drugs (2000) 13:215–226.
   Google Scholar
• NAPPI G, JOHNSON FN: The clinical efficacy of zolmitriptan. Rev Contemp. Pharmacother: (2000) 11:99–118.
   Google Scholar
• CADY RK, SHEFTELL F, LIPTON RB et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin. Ther: (2000) 22:1035–1048.
   PubMed Web of Science ®Google Scholar
• INTERNATIONAL 311C90 LONG-TERM STUDY GROUP The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. Headache 1998 38:173–183.
   Google Scholar
• GLEN RC, MARTIN GR, HILL AP et al:Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties. J. Med. Chem. (1995) 38:3566–3580.
   PubMed Web of Science ®Google Scholar
• MARTIN GR: Preclinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5-HT1B/ 1D agonist for migraine. Cephalalgia (1997) 17\(Suppl. 18):4–14.
   Google Scholar
• MARTIN GR, ROBERTSON AD, MACLENNAN SJ et al.: Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT 1B/1D partial agonist, 311 C90 (zolmitriptan). Br. J. Pharmacol (1997) 121:157–164.
   PubMed Web of Science ®Google Scholar
• SHEPHEARD SL, WILLIAMSON DJ, COOK DA, HILL RG, HARGREAVES RJ: Preclinical comparative studies on the sympatholytic effects of 5-HT1D receptor agonists in vivo. In: Headache Treatment: Trial Methodology and New Drugs. Olesen J, Tfelt-Hansen P (eds), Lippincott-Raven, Philadelphia, USA (1997):293–302.
   Google Scholar
• DIXON R, GILLOTIN C, GIBBENS M, POSNER J, PECK RW: The pharmacokinetics and effects on blood pressure of multiple doses of the novel antimigraine drug zolmitriptan (311C90) in healthy volunteers. Br. J. Clin. Pharmacol (1997) 43:273–281.
   PubMed Web of Science ®Google Scholar
• SMITH DA, CLEARY EW, WATKINS S et al.: Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study. J. Clin. Pharmacol (1998) 38: 685–693.
   PubMed Web of Science ®Google Scholar
• MOSKOWITZ MA: Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Set (1992) 13:307–311.
   PubMed Web of Science ®Google Scholar
• HUMPHREY PPA, GOADSBY PJ: The mode of action of sumatriptan is vascular? A debate. Cephalalgia (1994) 14:401–410.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L: Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann. Neurol (1988) 23:193–196.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L, EKMAN R: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol (1990) 28:183–187.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L: The trigeminovascular system and migraine: studies characterising cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol (1993) 33:48–56.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, HOSKIN KL: Inhibition of trigeminal neurons by intravenous administration of the serotonin (5-HT) 1B/ D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine? Pain (1996) 67(2-3):355–359.
   PubMed Web of Science ®Google Scholar
• MILLS A, RHODES P, MARTIN GR: [3H]311 C90 binding sites in cat brain stem: implications for migraine treatment. Cephalalgia (1995) 15 (Suppl. 14):116.
   Google Scholar
• GOADSBY PJ, KNIGHT YE: Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalagia (1997) 17:153–158.
   PubMed Web of Science ®Google Scholar
• HUGHES AM, DIXON R, DANE A et al.: Effects of zolmitriptan (zomig) on central serotonergic neurotransmission as assessed by active oddball auditory event-related potentials in volunteers without migraine. Cephalalgia (1999) 19:100–106
   PubMedGoogle Scholar
• PROIETTI-CECCHINI A, AFRA J, SCHOENEN J: Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5-HT1B/1D agonist zolmitriptan (311C90, Zomig). Cephalalagia (1997) 17:849–854.
   PubMed Web of Science ®Google Scholar
• DIXON R, HUGHES AM, NAIRN K et at.: Effects of the antimigraine compound zolmitriptan ('Zomig') on psychomotor performance alone and in combination with diazepam in healthy volunteers. Cephalalgia (1998) 18:468–475.
   Google Scholar
• MERCER AJ, LAMB RJ, ROLAN PE et al.: Lack of an effect of zolmitriptan (Zomig, 311C90) on psychometric task performance: results of a placebo-controlled study in healthy volunteers. Psychopharmacology (1998) 140:398–404.
   PubMedGoogle Scholar
• SEABER EJ, PECK RW, SMITH DA et al: The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. Br. Clin. Pharmacol (1998) 46:433–439.
   PubMed Web of Science ®Google Scholar
• SEABER E, ON N, PHILLIPS S et al: The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy volunteers. Br. J. Clin. Pharmacol (1996) 41:141–147.
   PubMed Web of Science ®Google Scholar
• DIXON R, WARRANDER A: The clinical pharmacokinetics of zolmitriptan. Cephalalgia (1997) 17\(Suppl. 18):15–20.
   Google Scholar
• WILD MJ, BUTTERS CJ, MCKILLOP D: Determination of the human hepatic cytochrome P450 isoenzymes involved in zolmitriptan and N-desmethyl zolmitriptan metabolism in vitro. Br. J. Clin. Pharmacol. (1998) 46:290P
   Google Scholar
• ROLAN P: Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia (1997) 17\(Suppl. 18):21–27.
   Google Scholar
• SMITH DA, CLEARY EW, WATKINS S et al: Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers. Int. J. Clin. Pharmacol Ther. (1998) 36:301–305.
   PubMed Web of Science ®Google Scholar
• SEABER E, ON N, DIXON RIVI et al.: The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br. Clin. Pharmacol (1997) 43:579–587.
   PubMed Web of Science ®Google Scholar
• THOMSEN LL, DIXON R, LASSEN LH et al.: 311C90 (zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia (1996) 16:270–275.
   PubMed Web of Science ®Google Scholar
• DIXON R, KEMP J, ENGLEMAN K et al.: A comparison of the pharmacokinetics and tolerability profile of zolmitriptan in adolescents and adults. Ear: J Nemo]. (1998) 5\(Suppl. 3):554. Abstract MTH22.
   Google Scholar
• PECK RW, SEABRE E, DIXON R et al.: The pharmacodynamics and pharmacokinetics of the 5HT1B/1D agonist zolmitriptan in healthy young and elderly men and women. Clin Pharmacol The]: (1998) 63(3):342–353.
   PubMedGoogle Scholar
• GILLOTIN C, BAGNIS C, MAMET JP et al: No need to adjust the dose of 311C90 (zolmitriptan), a novel antimigraine treatment, in patients with renal failure not requiring dialysis. Int. .1. Clin. Pharmacol Ther (1997) 35:522–526.
   PubMed Web of Science ®Google Scholar
• DIXON R, KEMP J: Effect of hepatic impairment on the pharmacokinetics of zolmitriptan. Clin. Pharmacol (1998) 38:694–701.
   Google Scholar
• HEADACHE CLASSIFICATION COMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia (1988) 8\(Suppl. 7):1–96.
   Google Scholar
• VISSER WH, KLEIN KB, COX RC et al.:311C90, a new central and peripherally acting 5-HT 1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology (1996) 46:522–526.
   PubMed Web of Science ®Google Scholar
• DOWSON AJ, MACGREGOR EA, PURDY RA, BECKER WJ, GREEN J, LEVY JL: Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia. (2002). In press.
   Google Scholar
• DAHLOF C, DIENER HC, GOADSBY PJ et al.: Zolmitriptan, a 5-HT 1B/1D receptor agonist for the acute oral treatment of migraine: a multi-centre, dose-range finding study. Eur. Neurol (1998) 5(6):535–543.
   Google Scholar
• SCHOENEN J, SAWYER J. Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1pi1D agonist: an overview of efficacy. Cephalalgia (1997) 17\(Suppl. 18):28–40
   Google Scholar
• BAHRA A, GAWEL MJ, HARDEBO JE, MILLS ON D, BREEN SA, GOADSBY PJ: Oral zolmitriptan is effective in the acute treatment of cluster headache. Neurology (2000) 54(9):1832–1839.
   PubMedGoogle Scholar
• TUCHMAN M, EDVINSONL, GERAUD G, KORCZYN A, MAUSKOP A, PFAFFENRATH V: Zolmitriptan provides consistent migraine relief when used in the long term. Curc Med. Res. Opin. (1999) 15(4):272–281.
   PubMedGoogle Scholar
• EDMEADS JG, MILLS ON DS: Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on 3000 subjects treated with zolmitriptan. Cephalalgia (1997) 17\(Suppl. 18):41–52.
   Google Scholar
• TEPPER SJ, DONNAN GA, DOWSON AJ et al.: A long-term study to maximise migraine relief with zolmitriptan. Curc Med. Res. Opin. (1999) 15(4):254–271.
   PubMed Web of Science ®Google Scholar
• TEPPER SJ, RAP OPORT AM: The triptans -a summary. CNS Drugs (1999) 12:403–417.
   Web of Science ®Google Scholar
• GOBEL H, PETERSEN-BRAUN M, HEINZE A: Which properties do patients expect of new and improved drugs in the treatment of primary headache disorders? In: Headache treatment: trial methodology and new drugs. Olesen J, Tfelt-Hansen P (eds), Lippincott-Raven Publishers, Philadephia, USA (1997):93–97.
   Google Scholar
• SILBERSTEIN SD: Migraine symptoms: results of a survey of self-reported migraineurs. Headache (1995) 36:387–396.
   Google Scholar
• PATRICK DL, HURST BC: Consistency of meaningful migraine relief (MMR) and quality of life in migraine patients receiving long-term treatment with 'Zomig'. Ear: J. Neurol (1998) 5\(Suppl. 3):550. Abstract MTH12.
   Google Scholar
• LEE D, PURDY A, CHARLESWORTH B, HUGHES J: Efficacy of zolmitriptan nasal spray in mild, moderate and severe migraine: relationship to timing of dosing. Cephalalgia (2001) 21 (4):419. Abstract P2–K33.
   Google Scholar
• MILLSON D: Clinical pharmacokinetics of the triptans: what are the important clinical issues? In: The Triptans, Novel Drugs for Migraine. Humphrey P; Ferrari M, Olesen J (eds), Frontiers in Headache Research, Oxford University Press, Oxford, UK (2001) 8:57–71.
   Google Scholar